Ensign Peak Advisors Inc Has $495,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Ensign Peak Advisors Inc decreased its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 78.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,139 shares of the company's stock after selling 33,174 shares during the quarter. Ensign Peak Advisors Inc's holdings in MoonLake Immunotherapeutics were worth $495,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its position in shares of MoonLake Immunotherapeutics by 3.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock worth $460,000 after purchasing an additional 320 shares during the period. Deutsche Bank AG raised its holdings in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after buying an additional 338 shares during the period. Geode Capital Management LLC raised its holdings in MoonLake Immunotherapeutics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock worth $3,192,000 after buying an additional 540 shares during the period. DnB Asset Management AS lifted its stake in MoonLake Immunotherapeutics by 11.3% in the fourth quarter. DnB Asset Management AS now owns 8,356 shares of the company's stock valued at $452,000 after buying an additional 847 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in shares of MoonLake Immunotherapeutics by 18.4% in the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock valued at $354,000 after buying an additional 1,013 shares during the period. Institutional investors own 93.85% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group dropped their price objective on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Wedbush reissued an "outperform" rating and issued a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price on the stock in a research note on Monday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $78.71.

MoonLake Immunotherapeutics Stock Performance

NASDAQ:MLTX traded down $0.37 during mid-day trading on Thursday, hitting $38.17. The stock had a trading volume of 55,362 shares, compared to its average volume of 353,306. MoonLake Immunotherapeutics has a twelve month low of $31.42 and a twelve month high of $58.26. The company's 50 day simple moving average is $38.45 and its 200 day simple moving average is $44.58. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -29.59 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.13. During the same period last year, the business earned ($0.22) earnings per share. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.